MOTS-c Research Notes
Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for MOTS-c. Research use only.
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.
MOTS-c is described as a mitochondrial-derived peptide. The selected studies use mouse, cell, or engineered-hydrogel models.
Questions covered by the selected literature
- Which metabolic pathways were measured
- How aged-cell and pressure-overload models differ
- Why an engineered material study is not a standalone product study
Evidence limits
The cited work is model-specific and does not establish a clinical outcome or product-use protocol.
A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.
Selected PubMed sources
- Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice.. J Cell Mol Med. 2022 Nov. PMID: 36156853.
- The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged human placenta-derived mesenchymal stem cells in vitro.. Mitochondrion. 2021 May. PMID: 33639272.
- MOTS-c-modified functional self-assembly peptide hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells of intervertebral disc degeneration.. Mater Today Bio. 2025 Jun. PMID: 40510834.
BioPep USA record
BioPep USA currently lists MOTS-c. Use the product page for current options and the documentation page for lot records.
Last reviewed: July 20, 2026.
